Anti-FGF19 antibody [11H3]

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

FGF19 also known as fibroblast growth factor 19 is a 251 amino acid protein with a molecular mass of approximately 27 kDa. It is mostly expressed in the liver small intestine and to some extent in the gallbladder. FGF19 is related to the FGF family of growth factors which are involved in a variety of developmental and physiological processes. Unlike many other FGF members FGF19 lacks a heparin-binding domain which influences its receptor binding characteristics. Researchers frequently use FGF19 ELISA kits and FGF19 assays to study this protein due to its significance in regulating bile acid metabolism.

Biological function summary

Fibroblast growth factor 19 participates in maintaining metabolic homeostasis and controlling bile acid synthesis. It acts by binding to a receptor complex composed of FGFR4 and beta-Klotho which signals the regulation of energy balance and interaction with other metabolic targets. FGF19 protein triggers pathways that modulate glucose and lipid metabolism making it an important factor in metabolic health. Its regulation of lipid and glucose processes emphasizes its role in metabolic control systems and potential impacts on obesity and diabetes management.

Pathways

The fibroblast growth factor 19 engages in two critical signaling routes: the MAPK/ERK and the PI3K/AKT pathways. These pathways are fundamental in cell proliferation differentiation and survival. FGF19 through FGFR4 activation influences regulatory proteins and factors downstream bridging interactions with other key molecules such as insulin and leptin pathways. This regulatory mechanism contributes to its ability to fine-tune a wide range of metabolic functions and influences energy balance.

Fibroblast growth factor 19 shows a significant connection to non-alcoholic fatty liver disease (NAFLD) and certain forms of cancer. Altered expression levels of FGF19 associate with liver conditions due to its role in bile acid regulation and energy homeostasis. In cancer particularly hepatocellular carcinoma the dysregulation of FGF19 and its receptor plays a part in unchecked cellular proliferation and tumorigenesis. Researchers have noted connections with proteins such as FGFR4 and beta-Klotho highlighting their collaborative roles in disease progression and potential therapeutic targeting strategies.